Research programme: HDAC1/2 inhibitors - Regenacy Pharmaceuticals

Drug Profile

Research programme: HDAC1/2 inhibitors - Regenacy Pharmaceuticals

Alternative Names: ACY 957; ACY-1035; RCY-1305

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acetylon Pharmaceuticals
  • Developer Regenacy Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Fetal haemoglobin stimulants; HDAC1 protein inhibitors; HDAC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Beta-thalassaemia; Cancer; Psychiatric disorders; Sickle cell anaemia

Most Recent Events

  • 04 Dec 2016 Preclinical development is ongoing fpr Sickle cell anaemia and Beta-Thalassemia in USA
  • 04 Dec 2016 Pharmacodynamics data from a preclinical trial in Sickle cell anaemia and Beta-Thalassemia released by Acetylon Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Beta-thalassaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top